September 2007 DSM

DSM accelerates shift to Life Sciences and Materials Sciences company and raises growth targets

Today, the newly composed Managing Board of Royal DSM N.V. presents the conclusions from its early, mid-term evaluation of the Vision 2010 - Building on Strengths strategy:
DSM accelerates the shift to a Life Sciences (Nutrition and Pharma) and Materials Sciences (Performance Materials) company:
  - this shift strongly positions DSM to meet the needs of tomorrows society in areas such as nutrition and health as well as advanced materials to improve the quality of life and the environment                                  
  - as a consequence DSM initiates a divestment program for non-core businesses and
  - steps-up search for acquisitions in core business areas to achieve external growth
Ambitious new growth targets
- organic sales growth target raised to >5% per year
- raised sales target for China in 2010 from USD 1 billion to USD 1.5 billion
Commitment to deliver EUR 1 billion additional sales from innovation by 2010
Dividend increase of 20% per share will be recommended at AGM in March 2008
New EUR 750 million share buy-back
Sustainability targets reconfirmed; energy savings target doubled
DSM raises the outlook for the full year 2007: Operating profit (before exceptional items) is expected to be EUR 820 million +/- 3% (up from EUR 790 million +/- 3%)
DSMs market leading positions and combined technological expertise in Life Sciences and Materials Sciences create a unique portfolio for growth and innovation,said Feike Sijbesma, Chairman of the Managing Board of DSM, and this accelerated Vision 2010 strategy gives us the ambition and urgency to capture its potential. By increasing our focus on these specialty areas of our business and freeing up resources for innovation and acquisitions, we believe this program will generate significant future value for our stakeholders.
The conclusions from DSMs mid-term evaluation of the Vision 2010 ? Building on Strengths strategy, originally presented at the annual DSM Analysts Conference in October 2005, are presented today. The review continues DSMs track record of successful portfolio adjustments and accelerates the groups shift to a specialty Life Sciences and Materials Sciences company, delivering faster growth, higher margins and improved earnings quality.
At the same time, the review confirms DSM
s three key strategic drivers of market-driven growth and innovation, an increased presence in emerging economies and operational excellence. A number of ambitious new growth objectives have been set, including raising the companys annual organic sales growth target from 3-5% to more than 5%. Additional shareholder value is expected to be created through a proposed uplift in the dividend per share and a new EUR 750 million share buy-back program.
Focus on Life Sciences and Materials Sciences
Following a fundamental review undertaken across the whole of the group
s business portfolio, DSM has taken the decision to focus on its specialty Life Sciences (Nutrition and Pharma) and Materials Sciences (Performance Materials) businesses. These businesses operate in sectors where DSM has market leading positions and utilize unique technology platforms which combine DSMs expertise in chemistry, process technology, (white/industrial) biotechnology and materials science.
s specialty life sciences and materials sciences businesses are serving rapidly growing societal needs, particularly in areas such as improving nutrition, health and the environment and enhancing peoples quality of life. They are global businesses. Their technology platforms can be used across numerous, diverse areas of application which provide multiple opportunities for growth whilst at the same time enabling high levels of sustainability. They also share a number of competences in both technologies and markets where cross fertilization between the units can be fostered, in particular within the areas of biotechnology and biomaterials, enabling DSM to be at the forefront in the creation of novel, bio-based
products from renewable resources. The four Emerging Business Areas (White Biotech, Personalized Nutrition, Biomedical and Specialty Packaging) fit very well in this thrust.
In the Vision 2010 period so far the target of 3-5% sales growth per year has clearly been beaten. DSM is confident that a higher growth target than originally foreseen can be achieved over the remainder of the Vision 2010 period. Therefore, DSM raises the organic sales growth target (in constant currencies) to more than 5% (based on assumed economic scenario).
By 2010, after this transformation of DSM to focus on Life Sciences and Material Sciences, DSM will be a stronger company with higher quality of earnings. DSM will be well positioned for increased ambitions thereafter.
Expanded scope for divestment and partnering
Those businesses which do not fit with the strategic thrust will
be carved out and divested, during the course of the Vision 2010 period, to new owners for whom there is a stronger strategic fit and under whose ownership they can prosper further. These businesses will be grouped in a new Base Chemicals & Materials cluster and include:
                               2007E Sales
Melamine / Urea / Fertilizers / Energy
(currently within Industrial Chemicals)
(~EUR 700 million)
(currently within Performance Materials)
(~EUR 500 million)
Special Products
(currently within Nutrition)
(~EUR 100 million)
Maleic anhydride including derivatives
(currently within Pharma)
(~EUR 75 million)
These divestments will result in a reduced presence at the Chemelot site, Geleen (NL).
DSM will review its options how it can best support the further development of that site into a successful industrial park. In addition, DSM will continue to invest in its R&D campus infrastructure on this site.
A partnering strategy will be pursued for DSM
s citric acid interests (currently within Nutrition, with 2007E Sales ~EUR 125 million), which will also be reported in the Base Chemicals & Materials cluster.
The new Base Chemicals & Materials cluster is expected to deliver 2007 sales of approximately EUR 1.5 billion, EBITDA of approximately EUR 200 million and EBIT of about EUR 100 million.

DSM Fibre Intermediates activities (currently within Industrial Chemicals), which provide backward integration for DSM Engineering Plastics and have a strong leadership position, will be reported in a new cluster Polymer Intermediates.

As a result of the above, DSM will create five reporting clusters, as follows:
Nutrition (Life Sciences)
Pharma (Life Sciences)
Performance Materials (Materials Sciences)
Polymer Intermediates (Materials Sciences)
Base Chemicals & Materials

The EBITDA margin targets of the clusters will be adjusted to reflect their new composition.
The new reporting structure will be effective for 2008 with restatement of 2007.
These portfolio adjustments are expected to be completed during the course of the Vision 2010 program. As a result, DSM will move closer towards its goal of deriving 60% of total revenues from specialty businesses, remaining only in those businesses formerly within the Industrial Chemicals cluster where backward-integration provides DSM with a competitive advantage.
In addition, over the remainder of the Vision 2010 period, DSM will seek to monetize the value of some other assets, mainly real estate.

In addition to achieving its objective of organic sales growth above 5%, DSM is lifting its ambitions for growth through acquisitions, which will be targeted in the company
s core Nutrition, Pharma and Performance Materials businesses, as well as in the Emerging Business Areas. It is intended that acquisitions, to be made during the period 2008-2010 and financed from DSMs strong cash flow, its balance sheet and from the proceeds of the various divestments to be undertaken, will add significantly to group revenues by 2010.
DSM will maintain its disciplined acquisition strategy.

Market-driven growth and innovation is a key driver in DSM
s Vision 2010 strategy and is expected to contribute significantly to growth. DSM is fully committed to the Vision 2010 target of generating an additional EUR 1 billion in sales from innovation by 2010 and is confident that the pipeline of products currently in development will enable this target to be met. The innovation program is expected to contribute more than EUR 300 million to the companys revenues in the current year, up from approximately EUR 170 million in 2006.
The additional annual innovation expenditure of currently EUR 40 million growing to EUR 70 million, announced at the commencement of the Vision 2010 program in 2005, will be maintained and investments will be made in technology and new product acquisitions, targeting at approximately EUR 75 million per year. This process is well under way; DSM recently acquired Pentapharm, a global leader in the production of active ingredients and system solutions for cosmetics which will help DSM Nutritional Products grow its presence develop and improve Pamako
s technology, and incorporate it in the existing DyneemaR life protection business.
Improved processes to maximize the benefits of DSM
s capabilities in innovation have been put in place and are working well. The Top 50 projects have been prioritized. The company has earmarked up to EUR 200 million for venturing investments until 2012.

Emerging Economies
DSM continues to experience strong growth in emerging economies. The particularly rapid development of the company
s presence in China, where DSM is currently achieving annual sales growth of around 20%, has enabled DSM today to raise its Vision 2010 growth objectives in China. The original target of USD 1 billion of revenues being derived from China by 2010 is now expected to be achieved well in advance of this time (2007 anticipated revenues: USD 900 - 950 million) and accordingly a new target of USD 1.5 billion by 2010 has now been set.

Operational Excellence
DSM has already announced two new programs in June this year to improve the performance and profitability of two businesses, DSM Anti-Infectives and the Aspire to Win program for DSM Nutritional Products, the latter of which is expected to deliver an annual minimum of EUR 100 million of improved profitability by 2010 and enable the Nutrition cluster to meet its Vision 2010 growth targets. DSM remains wholly committed to the pursuit of Operational Excellence and intends to continue and further strengthen the program with new initiatives in Advanced Manufacturing (for example, yield improvements and energy savings), Commercialization (product launch) and Excellerate (pricing program).

Sustainability (Triple P)
In the accelerated Vision 2010 strategy, DSM will continue to pursue its Sustainability / Triple P policy, paying keen attention to the performance of its activities not just on Profit, but also on People and the Planet. In the sector, the company ranks among the global leaders in sustainability and retention of global leadership in this area will be an ongoing priority for DSM. DSM continually strives to improve its eco-footprint and concrete targets have been set within the framework of Vision 2010 to further reduce emission levels. DSM has doubled its energy savings target from 1% to 2% per year. The company will seek to exploit the eco-advantages of DSM
s White Biotech industrial production capabilities which utilize renewable resources and are therefore beneficial both for the Planet and for Profit.
With regard to People, the ongoing diversification and internationalization of DSM
s workforce will be a continuing theme of the accelerated Vision 2010 strategy, benefiting the companys performance culture.

Financial Policy
As part of the evaluation of Vision 2010 ? Building on Strengths the following financial policy has been defined:
The companys gearing target (defined as net debt / total capital) of 30-40% is confirmed.
Cash will be allocated along the following priorities:
- capital expenditure (including acquisitions for new business development)
- increased dividends
- acquisitions
- share buy-backs
DSMs dividend policy will be adjusted to reflect the more stable, steadily increasing profitability of its specialty businesses. DSM aims to provide a stable and preferably rising dividend. A 20% dividend increase per ordinary share is to be recommended at the companys next Annual General Meeting in March 2008.
A new EUR 750 million share buy-back program will commence in October 2007 with a comparable scheme as in 2006/2007.
DSMs weighted average cost of capital (WACC) is 7.5% and the CFROI target (cash flow return on investment) will be 100 base points above WACC (up from the current level of 50 bps above the previous WACC of 8%).
DSM has adopted a systematic, risk-management oriented hedging strategy, with the objective of hedging approximately 50% of the companys net US Dollar currency exposure on a rolling annual basis.
Total shareholder return (TSR) remains the groups key performance metric and DSM will continue to target a TSR above the peer group average.
New, ambitious Vision 2010 targets
The successful execution of the accelerated Vision 2010 program will result in the continuing evolution of DSM into a specialty life sciences and materials sciences business.
The group will be strongly positioned for growth with the main drivers being delivered from market-driven innovation and an increasing presence in the world
s rapidly developing emerging economies, particularly China, as well as from acquisitions. DSMs ongoing commitment to Operational Excellence remains firmly in place.
The adoption of this strategy, with its objective of achieving a better quality earnings base from higher margin businesses, has enabled DSM to increase the Vision 2010 targets, as follows:
Vision 2010 Original Target New Target
Organic sales growth 3-5% >5%*
Cluster EBITDA margins
- Nutrition
- Pharma
- Performance Materials
- Polymer Intermediates



>13% (average)
Growth from innovation EUR 1 billion by 2010 EUR 1 billion by 2010
Growth in China USD 1 billion by 2010 USD 1.5 billion by 2010
CFROI WACC + 50 bp WACC + 100 bp
Specialty profile 50-60% Towards 60%
Sustainability Triple P policy Double energy savings
Other targets confirmed
Total shareholder return (TSR) Above average peer
Above average peer

* for the remainder of the period, based on assumed economic scenario

New bond issue
DSM is considering the refinancing of upcoming debt maturities in the fourth quarter with a new benchmark size Eurobond. A series of meetings with bond investors will be arranged, starting Monday 8 October 2007. The timing of the new issue will be subject to market developments.

Trading Update and Outlook
Trading conditions in some of DSM
s businesses are more favorable than earlier expected. Amongst others price developments in anti-infectives and in some parts of the nutrition business are positive due to a shifting demand-supply balance. DSM expects its operating profit (before exceptional items) for the full year 2007 to be EUR 820 million with an uncertainty of plus or minus 3% (up from EUR 790 million plus or minus 3%).

2007/9/27 DSM

DSM announces new breakthrough polymer PA4T

Royal DSM N.V. today announces the development of a new polymer which extends the portfolio for high performance engineering thermoplastics. The polymer, described as PA4T, has been developed by DSM Engineering Plastics, the inventor and global market leader in high performance polyamides with Stanyl® 46.

no details of its chemistry have been given, it must be assumed to be closely related to DSM's unique PA46, Stanyl.

The new polymer will answer to market trends for miniaturization and convergence of electronic devices like cell phones and computers. It will assist automakers in continued weight reduction efforts for better fuel efficiency and lower costs. PA4T exhibits an exciting and unique balance of properties including excellent dimensional stability, compatibility with lead free soldering, high stiffness and mechanical strength at elevated temperatures, high melting point, and excellent processability in terms of flow and processing window. 

Nico Gerardu, member of DSMs Managing Board and responsible for the Performance Materials cluster, is proud of the invention: It is very special that DSM introduces a new polymer to the market. Polymers started to enter the materials arena at the beginning of the 20th century, around the time that DSM was born. Most of the polymers used today were introduced to the market in the 30s till 60s. After 1980 very few new polymers were introduced. PA4T is the first new polymer to be introduced in the new millennium ? which is a true achievement of our research and business people and a true commitment to innovation. This breakthrough innovation fits perfectly with the acceleration of DSMs strategy Vision 2010 - Building on Strengths as announced today, which involves a strong focus on Life Sciences and Materials Sciences.

DSM envisions that PA4T materials are highly suitable for electronics applications such as memory card connectors, CPU sockets, high temperature bobbins, and notebook computer memory module connectors, based on its excellent compatibility in lead free surface mount technology and dimensional stability. In automotive markets, DSM expects the material to support new developments in under the hood applications relating to automotive electrical systems, fuel delivery, and cooling components.

DSM has filed patents on the new polymer, developed compounds and held initial investigative trials with market leaders for various end uses. Results to date have been impressive and DSM is currently constructing a market development plant at the Chemelot site in Sittard-Geleen, the Netherlands, which will provide quantities of the polymer for pre-marketing. The market development plant will become operational in the first quarter 2008.

This is an exciting opportunity for DSM Engineering Plastics and for our customers, who are being driven for higher performance in their applications and lower system costs delivered to their customers. PA4T is a promising complementary product in our portfolio. This development will support green initiatives such as lead free soldering and improved fuel economy. We are committed to moving as quickly as possible to bring this new material, which addresses these needs, to the market and to extend the number of applications where high performance polyamides can be effective," comments Roelof Westerbeek, Global Business Director High Performance Polyamides at DSM Engineering Plastics.

DSM Engineering Plastics
DSM Engineering Plastics is a business group in DSM
s Performance Materials cluster, with sales in 2006 of EUR 1005 million (which number includes the sales of DSM Dyneema) and approximately 1300 employees worldwide. It is one of the world's leading suppliers of engineering thermoplastics offering a broad portfolio of high performance products including Stanyl® PA 46 and Akulon® 6 and 66 polyamides, Arnitel® TPE-E, Arnite® PBT and PET polyesters, Xantar® polycarbonate and Yparex® extrudable adhesive resins. These materials are used in technical components for electrical appliances, electronic equipment and cars, in barrier packaging films as well as in many mechanical and extrusion applications. With Stanyl®, DSM Engineering Plastics is the global market leader in high heat polyamides. Akulon®, Arnite®, Arnitel®, Stanyl®, Xantar® and Yparex® are registered trademarks of DSM Engineering Plastics. Dyneema®, Dyneema Purity® and Dyneema®, the world's strongest fiberare trademarks and applications owned by Royal DSM N.V.

2008/3/5 DSM

DSM invests in development of bio-based materials in China

DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has participated in a USD 20 million financing round in Tianjin Green Bio-Science Co., Ltd (China). The proceeds will be used to build Chinas largest manufacturing plant for Polyhydroxyalkanoates (PHA) in the Tianjin Economic Development Area (TEDA).

微生物産生ポリエステル(ポリヒドロキシアルカン酸 PHA) は、バイオマス由来の有機物をある種の微生物に与えることにより得られる脂肪族ポリエステル

The investment is in line with DSMs ambitions to develop bio-based performance materials to meet customersgrowing needs for improved performance and environmental benefits at competitive costs. PHA offers, in response to the growing market need for eco-friendly solutions, a new biorenewable polymer platform for a broad range of applications from automotive to biomedical and electronics, including multiple forms like fibers, films and foams.

In parallel with the venture investment, DSM and TGBS intend to work together to create new business in bio-based performance materials.

This investment brings the total number of current company participations of DSM Venturing to 20. Venturing forms an integral part of DSMs open innovation approach, focused on teaming up with innovative players all over the world. The company has earmarked up to EUR 200 million for venturing investments until 2012. China is one of the core regions in the global investment strategy of DSM Venturing.

Babette Pettersen, Vice President New Business Development Performance Materials of DSM, said, Following earlier announcements on biopolymers, this TGBS investment and intended cooperation complements our ongoing development of bio-based performance materials. This will help to meet the growing market needs for eco-friendly solutions in a range of applications. As PHA is produced through fermentation by micro-organisms, it also offers the opportunity for DSM to extend its competencies both in Life Sciences and Material Sciences to a new family of biopolymers.

The investment in Tianjin Green Bio-Science is a further confirmation of DSMs global venturing strategy, in which China is one of the core regions. Moreover, it shows the companys commitment and dedication to actively promoting Chinas sustainable development initiatives, as one of the important elements in building a strong business position in China,said Weiming Jiang, President DSM China. The transition from petroleum-based materials to bio-based materials is a major global trend. With our expertise in biotechnology and in performance materials DSM is excellently positioned to facilitate this transition.

Mr. Lu Weichuan, General Manager of Tianjin Green Bio-Science Co., Ltd. expressed full confidence in the partnership and said, Through years of research and development, Tianjin Green Bio-Science has reached a leadership position within China for the production, extraction, processing and application of PHA. In addition to its financial investment in this partnership, DSM will also bring its international experience in life science and materials science. This cooperation will definitely speed up our growth and production of world-class biorenewable plastic products.

The plants construction will commence in Q2 2008, and is expected to start production in early 2009. It will have an annual production capacity of 10,000 tons of PHA.

DSM Venturing
DSM Venturing is an active investor in emerging companies and Venture Capital Funds in DSM
s strategic growth fields Nutrition, Pharma and Performance Materials. DSM Venturing's mission is to explore emerging markets and technologies in these strategic growth fields in order to enhance DSM's product portfolio and create value. DSM Venturing also plays an active role in the development of several new DSM business opportunities in the so-called emerging business areas Biomedical, Industrial (White) Biotechnology, Specialty Packaging and Personalized Nutrition. For more information about DSM Venturing see www.dsm

About Tianjin Green Bio-Science Co., Ltd.
Tianjin Green Biosciences Co., Ltd (TGBS), located in the High-Tech Park of Tianjin University in TEDA, Tianjin, is dedicated to developing and producing biodegradable polymers and products. Research demonstrates that the PHAs TGBS developed have excellent biodegradable, processing performance and biocompatibility. Due to its special properties, the PHA could be developed for use of high value added products including high strength fiber, pressure sensitive adhesive, aqueous adhesive, human tissue engineering product, etc., as well as applications in food and commodity packaging, with the potential to substitute 50% petroleum-based plastic in application.